Compare Novo Nordisk A/S (NVO) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Summit Therapeutics Inc — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while Summit Therapeutics Inc trades at $14.57 (market cap $10.48B). The key difference: Novo Nordisk A/S is far larger — about 21× Summit Therapeutics Inc's market cap, and Novo Nordisk A/S pays a 3.63% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| NVO | SMMT | |
|---|---|---|
Market Cap | $220.53B | $10.48B |
Sector | Health | Health |
52-Week High | $71.70 | $29.32 |
52-Week Low | $35.29 | $13.05 |
Enterprise Value | $239.49B | $9.90B |
Dividend Yield | 3.63% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
